Abstract
Melanoma is the type of skin cancer with the highest metastatic potential, resulting in its high mortality rate. The main mutations in melanoma occur in the MAPKs pathway: 50% of patients have alterations in BRAF; 15-20% in NRAS and mutations in NF1 or triple wild-type tumors account for the remaining cases. Although targeted therapy has revolutionized the treatment for melanoma through t…